Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MaxQ AI
Tel Aviv, Tel Aviv District, Israel
- Ownership
- Private
- Development stage
- Other
01
Overview
MaxQ AI's Accipio platform rapidly detects brain hemorrhages in CT scans; Accipio Ix is FDA cleared and CE Marked. Accipio Dx received FDA breakthrough designation. Clinical use is for prioritizing care in acute stroke and trauma settings, shown to enable faster and more confident diagnosis in emergency rooms.[2][3][5][6]
- Therapeutic areas
- Neurology
- Modalities
- DeviceSoftware
- Industry
- Medical Imaging
02
Partnerships
Samsung NeuroLogicaIBM Watson HealthGE HealthcareIntel
Beyond the preview
Go deeper on MaxQ AI.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MaxQ AI.